AU5092001A - Crystalline pharmaceutical - Google Patents

Crystalline pharmaceutical

Info

Publication number
AU5092001A
AU5092001A AU5092001A AU5092001A AU5092001A AU 5092001 A AU5092001 A AU 5092001A AU 5092001 A AU5092001 A AU 5092001A AU 5092001 A AU5092001 A AU 5092001A AU 5092001 A AU5092001 A AU 5092001A
Authority
AU
Australia
Prior art keywords
crystalline pharmaceutical
crystalline
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU5092001A
Other languages
English (en)
Inventor
Daniel A Dickman
Sanjay Chemburkar
James J Fort
Rodger F Henry
David Lechuga-Ballesteros
Yuping Niu
William Porter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27065762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU5092001(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US09/793,536 external-priority patent/US6608198B2/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of AU5092001A publication Critical patent/AU5092001A/xx
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10Oxygen or sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU5092001A 2000-03-30 2001-03-21 Crystalline pharmaceutical Pending AU5092001A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53825700A 2000-03-30 2000-03-30
US09/793,536 US6608198B2 (en) 2000-03-30 2001-02-27 Crystalline pharmaceutical
PCT/US2001/009112 WO2001074787A2 (en) 2000-03-30 2001-03-21 Crystalline pharmaceutical

Publications (1)

Publication Number Publication Date
AU5092001A true AU5092001A (en) 2001-10-15

Family

ID=27065762

Family Applications (3)

Application Number Title Priority Date Filing Date
AU5092001A Pending AU5092001A (en) 2000-03-30 2001-03-21 Crystalline pharmaceutical
AU2001250920A Revoked AU2001250920B2 (en) 2000-03-30 2001-03-21 Crystalline pharmaceutical
AU2006222711A Abandoned AU2006222711A1 (en) 2000-03-30 2006-09-27 Crystalline pharmaceutical

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2001250920A Revoked AU2001250920B2 (en) 2000-03-30 2001-03-21 Crystalline pharmaceutical
AU2006222711A Abandoned AU2006222711A1 (en) 2000-03-30 2006-09-27 Crystalline pharmaceutical

Country Status (22)

Country Link
EP (1) EP1268442A2 (xx)
JP (1) JP2003529592A (xx)
KR (1) KR100773258B1 (xx)
CN (2) CN101066952A (xx)
AR (2) AR033360A1 (xx)
AU (3) AU5092001A (xx)
BG (1) BG107165A (xx)
BR (1) BR0109433A (xx)
CA (1) CA2403635A1 (xx)
CZ (1) CZ20023529A3 (xx)
HU (1) HUP0302675A3 (xx)
IL (1) IL151551A0 (xx)
MX (1) MXPA02009559A (xx)
MY (1) MY128296A (xx)
NO (1) NO325005B1 (xx)
NZ (1) NZ521183A (xx)
PE (1) PE20011232A1 (xx)
PL (1) PL359727A1 (xx)
SA (2) SA06270303B1 (xx)
SK (1) SK14832002A3 (xx)
TW (1) TWI284640B (xx)
WO (1) WO2001074787A2 (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608198B2 (en) 2000-03-30 2003-08-19 Abbott Laboratories Crystalline pharmaceutical
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8445506B2 (en) 2009-02-06 2013-05-21 Hetero Research Foundation Polymorphs of lopinavir
US8637449B2 (en) * 2009-08-27 2014-01-28 Merck Sharp & Dohme Corp. Processes for preparing protease inhibitors of hepatitis C virus
CN112830899A (zh) * 2021-01-18 2021-05-25 合肥华方医药科技有限公司 一种洛匹那韦新晶型及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
WO1998057648A1 (en) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound

Also Published As

Publication number Publication date
SA01220270B1 (ar) 2006-11-14
IL151551A0 (en) 2003-04-10
CA2403635A1 (en) 2001-10-11
SK14832002A3 (sk) 2003-02-04
BG107165A (bg) 2003-07-31
KR20030011807A (ko) 2003-02-11
AR033360A1 (es) 2003-12-17
NO20024679D0 (no) 2002-09-30
TWI284640B (en) 2007-08-01
AU2001250920B2 (en) 2006-06-29
PL359727A1 (en) 2004-09-06
EP1268442A2 (en) 2003-01-02
NO325005B1 (no) 2008-01-14
AR049560A2 (es) 2006-08-16
HUP0302675A2 (hu) 2003-12-29
JP2003529592A (ja) 2003-10-07
MY128296A (en) 2007-01-31
CN1330639C (zh) 2007-08-08
PE20011232A1 (es) 2001-12-08
SA06270303B1 (ar) 2009-08-02
NZ521183A (en) 2004-03-26
BR0109433A (pt) 2004-08-10
WO2001074787A2 (en) 2001-10-11
CN101066952A (zh) 2007-11-07
NO20024679L (no) 2002-09-30
KR100773258B1 (ko) 2007-11-05
WO2001074787A3 (en) 2002-02-07
MXPA02009559A (es) 2003-05-21
AU2006222711A1 (en) 2006-10-19
CZ20023529A3 (cs) 2003-02-12
CN1422259A (zh) 2003-06-04
HUP0302675A3 (en) 2004-03-29

Similar Documents

Publication Publication Date Title
GB0006133D0 (en) Novel pharmaceutical
GB0025473D0 (en) Pharmaceutical combinations
GB0020691D0 (en) Pharmaceutical combination
GB0031084D0 (en) Pharmaceutical compounds
GB0012291D0 (en) Pharmaceutical combination
GB0019272D0 (en) Pharmaceutical compounds
GB0019228D0 (en) Novel pharmaceutical
GB0021865D0 (en) Novel pharmaceutical
IL151551A0 (en) Crystalline pharmaceutical
GB0129273D0 (en) Crystalline drug form
GB0024318D0 (en) Pharmaceutical compounds
GB0014006D0 (en) Novel pharmaceutical
GB0019224D0 (en) Novel pharmaceutical
GB0019226D0 (en) Novel pharmaceutical
GB0005366D0 (en) Pharmaceutical compounds
GB0021487D0 (en) Pharmaceutical
GB0014005D0 (en) Novel pharmaceutical
GB0023971D0 (en) Novel pharmaceutical
GB0021785D0 (en) Novel Pharmaceutical
GB0019223D0 (en) Novel pharmaceutical
GB0023970D0 (en) Novel pharmaceutical
GB0012293D0 (en) Pharmaceutical combination
GB0006601D0 (en) Crystalline alkycycline derivative
EG24200A (en) Novel pharmaceutical
GB0031579D0 (en) Pharmaceutical compounds